A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.

Katja Werlenius,Giuseppe Stragliotto,Michael Strandeus,Malin Blomstrand,Helena Carén,Asgeir S Jakola,Bertil Rydenhag, Dorte Dyregaard,Karine N Dzhandzhugazyan,Alexei F Kirkin, Martin K Raida,Anja Smits,Sara Kinhult

Neuro-oncology advances（2021）

引用 3|浏览18

暂无评分

摘要

Addition of ALECSAT immunotherapy to standard treatment with radiochemotherapy was well tolerated but did not improve PFS or OS for patients with newly diagnosed GBM.

查看译文

关键词

ALECSAT,adoptive cell therapy,glioblastoma,immunotherapy,randomized trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要